<?xml version='1.0' encoding='utf-8'?>
<document id="28548030"><sentence text="Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs)." /><sentence text="1" /><sentence text=" Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) and has been clinically utilized to prevent the rejection of organ transplants"><entity charOffset="51-60" id="DDI-PubMed.28548030.s3.e0" text="rapamycin" /></sentence><sentence text=" This study aims to determine the inhibition of everolimus on the activity of phase-II drug-metabolizing enzymes UDP-glucuronosyltransferases (UGTs)"><entity charOffset="48-58" id="DDI-PubMed.28548030.s4.e0" text="everolimus" /></sentence><sentence text=" 2" /><sentence text=" The results showed that 100 μM of everolimus exerted more than 80% inhibition toward UGT1A1, UGT-1A3 and UGT-2B7"><entity charOffset="35-45" id="DDI-PubMed.28548030.s6.e0" text="everolimus" /></sentence><sentence text=" UGT1A3 and UGT2B7 were selected to elucidate the inhibition mechanism, and in silico docking showed that hydrogen bonds and hydrophobic interactions mainly contributed to the strong binding of everolimus toward the activity cavity of UGT1A3 and UGT2B7"><entity charOffset="106-114" id="DDI-PubMed.28548030.s7.e0" text="hydrogen" /></sentence><sentence text=" Inhibition kinetic-type analysis using Lineweaver-Burk plot showed competitive inhibition toward all these UGT isoforms" /><sentence text=" The inhibition kinetic parameters (Ki) were calculated to be 2" /><sentence text="3, 0" /><sentence text="07 and 4" /><sentence text="4 μM for the inhibition of everolimus toward UGT1A1, UGT-1A3 and UGT-2B7, respectively" /><sentence text=" 3" /><sentence text=" In vitro-in vivo extrapolation (IVIVE) showed that [I]/Ki value was calculated to be 0" /><sentence text="004, 0" /><sentence text="14 and 0" /><sentence text="002 for UGT1A1, UGT-1A3 and UGT-2B7, respectively" /><sentence text=" Therefore, high DDI potential existed between everolimus and clinical drugs mainly undergoing UGT1A3-catalyzed glucuronidation"><entity charOffset="47-57" id="DDI-PubMed.28548030.s18.e0" text="everolimus" /></sentence><sentence text="" /></document>